top of page
hand black logo no dogs.png

My Dog Is On The Pill

Developing a cure for
animal overpopulation:
a cookie to spay and neuter
... without surgery.

Please sign the petition below!

Urge Gilead CEO to authorize cure for deadly cat virus! 

Dear Daniel O'Day and Gilead,


Please authorize the use of GS-441524 for the treatment of Feline Infectious Peritonitis in the U.S. and worldwide. This would save the lives of many cats and prevent many cat guardians from suffering the heartbreak of losing their beloved companion animals to this disease.


FIP is a devastating disease that affects cats worldwide, almost always leading to death. The discovery of GS-441524 and its effectiveness in clinical trials has brought hope to many. However, the lack of licensing for veterinary use has left a gaping hole in the resources available to fight this disease.


Gilead Sciences has been at the forefront of groundbreaking medical advancements, including the development of GS-441524. While we understand that the focus has been on developing treatments for human disease such as COVID-19, we strongly urge you to consider the vital impact that licensing GS-441524 for veterinary use could have on cats and their human guardians.


The current situation has driven desperate cat guardians to seek this medication through unregulated channels, risking counterfeit or ineffective treatments. This not only endangers the health of cats but also places a huge emotional and financial burden on their guardians.


We believe that Gilead Sciences has the unique opportunity to make a profound difference in the lives of countless cats and their families by making GS-441524 legally and readily available for veterinary use worldwide.


Please authorize the use of GS-441524 for FIP treatment. By doing so, you would be reinforcing Gilead Sciences' commitment to improving lives, regardless of the species.



Please fill out the form below. When you click "Sign the petition," your signed petition will automatically be emailed to the to CEO of Gilead, Daniel O’Day.

bottom of page